Our data display that CB1 rather than CB2 mediates the chemotaxis of neutrophils and NETosis, and CB1 blockade with AM281 reduces the infiltration and NETosis of neutrophils and attenuates liver injury in vivo, which can be used as a novel target for the treatment of liver fibrosis. The gene discussed is CNR1; the disease is Hepatic fibrosis.